GT Biopharma, Inc. (GTBP)
USD 2.05
(-21.46%)
USD 2.05
(-21.46%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.85 Million | -15.21 Million | -15.6 Million | -7.26 Million | -3.65 Million | -10.67 Million |
| Net Income | -7.59 Million | -20.88 Million | -58.01 Million | -28.29 Million | -38.64 Million | -259.18 Million |
| Depreciation & Amortization | - | - | - | 317 Thousand | 4000.00 | 7000.00 |
| Deferred income taxes | - | - | - | -317 Thousand | 25.09 Million | 228.51 Million |
| Stock-based compensation | 2.2 Million | 7.64 Million | 33.92 Million | 269 Thousand | 5.3 Million | 9.69 Million |
| Change in working capital | 1.82 Million | -1.98 Million | 7.94 Million | 2.4 Million | 2.93 Million | 111 Thousand |
| Other non-cash items | -5.28 Million | 10 Thousand | 538 Thousand | 18.36 Million | 1.64 Million | 10.18 Million |
| Investing Cash Flow | -2 Million | 12.14 Million | -23.04 Million | - | 200 Thousand | -36 Thousand |
| Investments in PPE | - | - | - | - | - | -36 Thousand |
| Acquisitions | - | - | - | - | 200 Thousand | - |
| Investment purchases | -2 Million | 12.14 Million | -23.04 Million | - | - | - |
| Sales/Maturities of investments | - | 12.14 Million | - | - | - | - |
| Other Investing Activities | -2009.00 | -12.14 Million | -23.04 Thousand | - | 200.00 | -36 Thousand |
| Financing Cash Flow | 6.26 Million | -224 Thousand | 42.31 Million | 12.53 Million | 3.42 Million | 10.19 Million |
| Debt repayment | - | - | -1.2 Million | -12.53 Million | -100 Thousand | -4.41 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -224 Thousand | - | - | - | - |
| Common Stock Issuance | 6.26 Million | 35 Thousand | 41.11 Million | 1.74 Million | 1.36 Million | 325 Thousand |
| Other Financing Activities | 6.26 Million | -35 Thousand | 42.31 Million | 23.32 Million | 2.16 Million | 14.28 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 1.96 Million | -2.03 Million | 7.07 Million | -838 Thousand | 3.15 Million | 136 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -137 Thousand | 41 Thousand | 863 Thousand | 3.24 Million | -216 Thousand | -25 Thousand |
| Cash at beginning of period | 5.67 Million | 8.96 Million | 5.29 Million | 28 Thousand | 60 Thousand | 576 Thousand |
| Cash at end of period | 1.07 Million | 5.67 Million | 8.96 Million | 5.29 Million | 28 Thousand | 60 Thousand |
| Capital Expenditure | - | - | - | - | - | -36 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -4.59 Million | -3.29 Million | 3.67 Million | 5.26 Million | -32 Thousand | -516 Thousand |
| Free Cash Flow | -8.85 Million | -15.21 Million | -15.6 Million | -7.26 Million | -3.65 Million | -10.71 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -3.71 Million | -2.26 Million | -7.59 Million | -2.96 Million | -2.41 Million | -1.99 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 120 Thousand | 102 Thousand | 2.2 Million | 387 Thousand | 500 Thousand | 398 Thousand |
| Change in working capital | 147 Thousand | -1.36 Million | 1.82 Million | 376 Thousand | 395 Thousand | 1.04 Million |
| Other non-cash items | -89 Thousand | 818.99 Thousand | -5.28 Million | 106 Thousand | -805 Thousand | -1.24 Million |
| Investing Cash Flow | 7.85 Million | 5.03 Million | -2 Million | 478 Thousand | 1.84 Million | 2.65 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | 5.03 Million | -2 Million | 478 Thousand | 1.84 Million | 2.65 Million |
| Sales/Maturities of investments | 7.85 Million | 5.03 Million | - | - | - | - |
| Other Investing Activities | 7.85 Million | 5.03 Million | -2009.00 | 478.00 | 1845.00 | 2657.00 |
| Financing Cash Flow | 2.97 Million | - | 6.26 Million | -400 Thousand | - | - |
| Debt repayment | - | - | - | -82 Thousand | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 2.97 Million | - | 6.26 Million | -400 Thousand | 400 Thousand | - |
| Other Financing Activities | 2.97 Million | - | 6.26 Million | 82 Thousand | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 116 Thousand | -1.34 Million | 1.96 Million | 525 Thousand | 379 Thousand | 1.08 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 31 Thousand | -22 Thousand | -137 Thousand | -149 Thousand | -379 Thousand | -38 Thousand |
| Cash at beginning of period | 1.95 Million | 1.07 Million | 5.67 Million | 2.64 Million | 2.76 Million | 2.04 Million |
| Cash at end of period | 2.67 Million | 1.95 Million | 1.07 Million | 1.07 Million | 2.64 Million | 2.76 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | -498 Thousand | 498 Thousand | - |
| Net cash flow / Change in cash | 729 Thousand | 871 Thousand | -4.59 Million | -1.56 Million | -119 Thousand | 722 Thousand |
| Free Cash Flow | -3.53 Million | -4.16 Million | -8.85 Million | -2.04 Million | -1.96 Million | -1.93 Million |
GOD
M11
MSTR
3494
BBLG
SYS1